ARCHIVE
Resources
Principal content
Chronic disease conditions could attract pharma-accountable care organization collaboration
Data mining, patient treatment patterns may be the best avenues for pharma to explore by BioPharm Insight
CDC mulls new strategies to improve HCV testing required to link patients to care
New study finds only 51% of patients receive all required testing by BioPharm Insight
Europe regulators not yet on board with adult ADHD due to concerns regarding diagnosis methods
Tide could be turning as companies continue to eye this space and experts point to healthcare cost savings by BioPharm Insight
German drug rebate future at centre of debate as industry versus payer battle intensifies
Industry puts pressure on German government to lower 16% rebates on branded pharmaceuticals by BioPharm Insight
J&J’s Remicade six-month patent extension to stave off Celltrion biosimilar threat in major EU markets
Remicade now protected until 2015 in EU countries where patent is in force, including the top five markets by BioPharm Insight
Celltrion slides to third in race for Roche rituximab biosimilar with planned 2H13 Phase III trial start
Phase III trial was thought to be ongoing since 2011 but never actually started. by BioPharm Insight
UK’s value-based pricing pilot schemes seen as path forward to preserve political promises
Pilot schemes for select indications could allow for gradual VBP implementation. by BioPharm Insight
Teva’s Azilect unlikely to see additional utility in early Parkinson’s based on recent trial results
Global label expansion as add on to dopamine agonists is reasonable. by BioPharm Insight
AstraZeneca’s Brilinta not impacted by reimbursement barriers though US uptake remains tough
US cardiologists still skeptical of clot buster’s benefit on top of aspirin. by BioPharm Insight
UK value-based pricing will struggle to materialise as year-end deadline approaches
Reservations persist for January 2014 consolidation on the VBP overhaul, and a modified pricing scheme may be likely. by BioPharm Insight




